Diabetic Thyroid Cancer Health Risk Alert: Byetta Has Recently Been Linked To An Increased Risk of Thyroid Cancer By Diabetic Thyroid Cancer Lawyer

Diabetic Thyroid Cancer Health Risk Alert: Some Diabetes Drugs Have Recently Been Linked To An Increased Risk of Thyroid Cancer By Diabetic Thyroid Cancer Lawyer Jason S. Coomer

In 2012, more than 200,000 people were newly diagnosed with thyroid cancer.  A growing number of people with thyroid cancer are diabetics.  While some diabetic drugs are known to cause an increased risk of thyroid cancer and this increased risk is on the warning label, other diabetic drugs do not have warnings regarding an increased risk of thyroid cancer.  

The diabetes drug, Byetta, currently does not have a warning regarding an increased risk of thyroid cancer, however, some recent studies have suggested that the diabetes drug, Byetta, increases the risk of thyroid cancer.  As such, several Byetta Thyroid Cancer lawsuits are currently being reviewed that allege that the maker of Byetta has failed to provide adequate warnings to consumers and the medical community of this cancer risk resulting in serious injury and death from thyroid cancer.

Individuals that have been diagnosed with thyroid cancer and have taken Byetta as well as families that have lost a loved one to thyroid cancer and that loved one was taking Byetta may be entitled to financial compensation and are strongly encouraged to have their potential case reviewed.  For more information on Byetta Thyroid Cancer Lawsuits, please feel free to contact Byetta Thyroid Cancer Lawyer, Jason Coomer, or use our online submission form.

FDA Adverse Events Have Shown Byetta May Cause An Increased Risk of Thyroid Cancer and Pancreatic Cancer: Persons Taking Byetta That Have Been Diagnosed With Pancreatic Cancer or Thyroid Cancer as well as Their Doctors and Families Are Encouraged To Report Adverse Events To The FDA

 
In July 2011, researchers at the University of California, Los Angeles studied the connection between Byetta and pancreatic cancer, pancreatitis, and thyroid cancer by combing FDA adverse events reports. They calculated a sixfold increase in users developing pancreatitis, and Byetta increased the likelihood of pancreatic cancer by 2.9 times. The lead researcher, Dr. Peter Butler, cautioned that the results do not account for increased Byetta side effects reporting by doctors. The study appeared in the journal of Gastroenterology. 
 

In 2009, the U.S. Food and Drug Administration (FDA) published a Drug Safety Communication to announce that drug-makers Amylin Pharmaceuticals and Eli Lilly Co. must conduct 6 post-marketing surveillance studies to better understand the potential link between Byetta and thyroid cancer. The result of these studies are still pending.

Persons who are taking Byetta and who have been diagnosed with pancreatic cancer or thyroid cancer and their families are strongly encouraged to report adverse events to the FDA to ensure that all cancer risks are properly reviewed and placed on any future Byetta warnings.